BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/13/2015 10:06:00 AM | Browse: 1662 | Download: 2541
Publication Name World Journal of Hepatology
Manuscript ID 15661
Country Australia
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure
Manuscript Source Invited Manuscript
All Author List Venessa Pattullo
Funding Agency and Grant Number
Corresponding Author Dr. Venessa Pattullo, MBBS, FRACP, PhD, Department of Gastroenterology, Royal North Shore Hospital, 4B Acute Services Building, St Leonards NSW 2065, Sydney, Australia. venessa.pattullo@sydney.edu.au
Key Words Immunosuppression; Hepatitis B; Hepatitis B virus reactivation; Prophylaxis; Lamivudine; Chemotherapy; Entecavir; Tenofovir; Rituximab
Core Tip Hepatitis B virus reactivation is a potentially fatal but preventable complication of chemotherapy and immunosuppression. Both chronically infected [hepatitis B surface antigen (HBsAg) positive] and previously exposed (HBsAg negative/anti-HBc positive) patients are susceptible, the risk observed to be strongly associated with the potency of the immunosuppressive drug regime and the baseline virological status. The knowledge gaps that require further investigation in the optimal management of this phenomenon are discussed in this review. Recom-mendations regarding screening, monitoring and the role of antiviral prophylaxis are outlined with reference to current international associations’ guidelines and the best available evidence to date.
Publish Date 2015-05-13 10:06
Citation Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol 2015; 7(7): 954-967
URL http://www.wjgnet.com/1948-5182/full/v7/i7/954.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i7.954
Full Article (PDF) WJH-7-954.pdf
Full Article (Word) WJH-7-954.doc